Harbour BioMed (HKEX: 02142), a Hong Kong-based global biopharmaceutical company, announced on Sunday that it has dosed the first patient in its ongoing phase I trial of the first-in-class anti-B7H7 (HHLA2) antibody HBM1020 (NCT05824663/Study 1020.1) in the United States.
The study is assessing the safety, tolerability, pharmacokinetics, and anti-tumour activity of HBM1020 in subjects with advanced solid tumours. HBM1020 is generated from the Harbour Mice H2L2 transgenic mice platform and is claimed to be the first therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development worldwide.
Dr Jingsong Wang, Harbour BioMed founder, chairman and CEO, said, 'We are delighted to announce the dosing of the first patient with our first-in-class B7H7/HHLA2 antibody HBM1020. This milestone is a significant accomplishment for our team and represents a major step forward in our mission to transform patient care. We are excited about the potential of the B7H7/HHLA2 antibody to make a meaningful difference in the lives of patients suffering from advanced malignancies and we remain dedicated to advancing its clinical development globally.'
Merck's sotatercept gains priority review for PAH treatment
Antibe gains approval for otenaproxesul PK/PD study
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial
Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy
Sanofi granted Priority Review for EoE treatment in young children
Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)
BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment